Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 1,815 Shares

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 1,815 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $56.39, for a total value of $102,347.85. Following the completion of the sale, the executive vice president now owns 3,598 shares of the company’s stock, valued at approximately $202,891.22. This trade represents a 33.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, February 10th, Jennifer Kayden Lee sold 4,189 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $58.91, for a total value of $246,773.99.
• On Tuesday, February 4th, Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $59.43, for a total value of $85,995.21.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM stock opened at $56.69 on Friday. The stock’s 50 day simple moving average is $57.06 and its 200 day simple moving average is $53.59. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. SRS Capital Advisors Inc. raised its stake in shares of Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after acquiring an additional 400 shares in the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $28,000. SBI Securities Co. Ltd. bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $37,000. R Squared Ltd bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $44,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Rhythm Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211 shares of the company’s stock valued at $114,000 after acquiring an additional 391 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on RYTM shares. The Goldman Sachs Group upped their target price on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $80.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. TD Cowen increased their price objective on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC increased their price objective on Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Rhythm Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.09.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.